CEO Dismissal Sparks High-Stakes Legal Dispute
Former Contour Clinics CEO Mike Canizales has launched a Federal Court lawsuit against the cosmetic chain and its co-founder, Dr Josh Wall, alleging he was unlawfully dismissed weeks before becoming entitled to a multimillion-dollar payout.
Canizales, who took on the role in January 2024 with a reported annual salary of $350,000, claims his termination in August 2025 was strategically timed. The dismissal came shortly after the company reached an estimated valuation of $160 million, which he argues triggered his entitlement to up to $27.2 million under an alleged equity agreement.
According to a 31-page statement of claim, Canizales maintains he only accepted the CEO position on the condition that he would share in any future capital raising or sale event. He alleges the company’s leadership acted to prevent that payout by removing him from the role before the agreement could be realised.
The lawsuit centres on claims of unfair dismissal tied to a multimillion-dollar equity agreement. [The Mercury]
Why the Case Raises Concerns Across the Cosmetic Industry
The dispute highlights the legal risks surrounding executive compensation arrangements in rapidly growing private companies, particularly where agreements may not be formally documented.
Australia’s cosmetic and aesthetics sector has expanded significantly in recent years, driven by social media influence and growing consumer demand for non-surgical treatments. As businesses in the space attract higher valuations and investor interest, disputes tied to equity incentives are becoming more likely.
The case also carries reputational implications due to Contour Clinics’ high-profile client base, which includes reality television personalities and influencers. Allegations raised in the claim—ranging from misconduct to financial irregularities—have intensified public attention, although these claims are strongly denied by the respondents.
Contour Clinics and Key Figures at the Centre of the Battle
Contour Clinics, founded in 2017 by Dr Josh Wall and Ben Thurlow, operates eight locations across Sydney and Brisbane. The company has grown into a recognised name in Australia’s non-surgical cosmetic treatment market, with a valuation estimated at $160 million as of mid-2025.
Contour Clinics has become a prominent name in Australia’s cosmetic treatment industry. [Contour Clinics]
Mike Canizales, the claimant, argues he is owed a substantial share tied to that valuation. He previously secured a multimillion-dollar settlement in a legal dispute involving Microsoft more than two decades ago.
Dr Josh Wall, a co-founder of the business, is the primary respondent in the case. He has denied all allegations made against him, including claims relating to personal conduct and financial management. He was cleared of drug-related allegations by the Medical Council of New South Wales in February 2025.
Ben Thurlow, also a co-founder, has not been directly implicated in the personal allegations but remains central to the company’s ownership structure.
Federal Court Case Draws Attention Across Australia’s East Coast
The case has been filed in the Federal Court of Australia, which handles complex commercial disputes. Contour Clinics’ operations are concentrated along the east coast, with clinics in Sydney and Brisbane, but its brand recognition extends nationally due to its association with television personalities from shows such as Married at First Sight.
Industry observers are closely monitoring the proceedings, as the outcome may influence how executive contracts and equity arrangements are structured in Australia’s private healthcare and wellness sectors.
The case has been filed in the Federal Court of Australia, where complex commercial disputes are handled. [IStock]
Timeline: From Appointment to Legal Showdown
Contour Clinics was established in 2017, laying the foundation for its expansion in the cosmetic treatment industry.
In January 2024, Canizales joined the company as CEO under an agreement that he claims included equity participation in future transactions.
By February 2025, Dr Wall had been cleared of drug-related allegations following an investigation by the Medical Council of New South Wales.
In July 2025, the company reached an estimated valuation of $160 million, which Canizales argues triggered his entitlement to a significant payout.
Just one month later, in August 2025, he was suspended and dismissed for alleged misconduct, which he denies.
In November 2025, Dr Wall stepped away from the business to focus on personal health matters.
By March 2026, the legal dispute had entered the public domain, with the defence expected to be filed on Good Friday.
How the Dispute Unfolded Behind the Scenes
Canizales alleges the dispute stems from an agreement tied to the company’s growth trajectory. He claims the understanding was that he would benefit financially if the business reached a major valuation milestone or underwent a transaction.
Following the July 2025 valuation, he argues that the company moved to terminate his employment to avoid honouring that agreement. The reasons cited for his dismissal included alleged misrepresentation of his professional history and undisclosed past business dealings.
The statement of claim also outlines a series of personal allegations against Dr Wall, including claims relating to substance use and financial irregularities. These allegations are denied in full by both Dr Wall and Contour Clinics.
What Happens Next in the Federal Court Proceedings
The case remains in its early stages, with the defence yet to be formally filed. If the matter proceeds to trial, the court will examine whether the alleged equity agreement is legally enforceable.
This will likely depend on the existence and clarity of any written documentation supporting the arrangement. Without formal agreements, courts often face challenges in determining the validity of such claims.
While the personal allegations may affect reputational perceptions, the court is expected to focus primarily on the contractual and legal aspects of the dispute unless a direct connection to the dismissal is established.
Legal Risks and Key Arguments From Both Sides
Contour Clinics is expected to argue that Canizales’ termination was justified based on alleged misconduct. If proven, this could undermine his claim to any financial entitlement linked to his role.
On the other hand, Canizales will seek to demonstrate that the dismissal was not only unjustified but strategically executed to avoid a substantial payout.
Legal experts note that cases involving informal or partially documented equity agreements often hinge on the strength of evidence and the consistency of communications between parties.
Also Read: Catapult Sports FY26 ACV Growth Forecast Hits 28%
Final Thoughts
The Federal Court dispute between Mike Canizales and Contour Clinics underscores the growing complexities of executive compensation in high-growth private businesses.
At the centre of the case is a fundamental question: whether an alleged equity promise made during recruitment can withstand legal scrutiny when challenged in court.
As proceedings unfold, the outcome may serve as a key reference point for companies and executives navigating similar arrangements in Australia’s evolving cosmetic and wellness industry.
FAQS
Q1: Who filed the lawsuit against Contour Clinics?
A: Former CEO Mike Canizales filed the lawsuit in the Federal Court of Australia.
Q2: What is the main claim in the case?
A: He claims he was unfairly dismissed to prevent a payout of up to $27.2 million tied to the company’s valuation.
Q3: When was Mike Canizales dismissed?
A: He was suspended and dismissed in August 2025.
Q4: What triggered the $27 million entitlement?
A: The company’s estimated $160 million valuation in July 2025.
Q5: How have Contour Clinics and Dr Josh Wall responded?
A: They have denied all allegations, including claims of misconduct and financial issues.
Q6: Where is the case being heard?
A: The case has been filed in the Federal Court of Australia.
Q7: What could be the outcome of this case?
A: The court will decide whether the alleged equity agreement is enforceable and whether the dismissal was lawful.
Disclaimer:
This article is published by Colitco for informational purposes only and is based on publicly available information regarding Contour Clinics and related legal proceedings. The claims outlined remain allegations before the court and have not been proven. Colitco does not make any representations as to the accuracy or completeness of the information and does not provide legal or financial advice.
Sources
https://www.goldcoastbulletin.com.au/business/work/leaders-companies
https://www.ntnews.com.au/business/work/leaders-companies
Last modified: March 27, 2026
